These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 19746526)

  • 1. Bevacizumab + sunitinib: microangiopathic haemolytic anaemia. A serious drug interaction between 2 cancer drugs.
    Prescrire Int; 2009 Aug; 18(102):165. PubMed ID: 19746526
    [No Abstract]   [Full Text] [Related]  

  • 2. From theoretical synergy to clinical supra-additive toxicity.
    Soria JC; Massard C; Izzedine H
    J Clin Oncol; 2009 Mar; 27(9):1359-61. PubMed ID: 19224836
    [No Abstract]   [Full Text] [Related]  

  • 3. Toxicity of sunitinib plus bevacizumab in renal cell carcinoma.
    Rini BI; Garcia JA; Cooney MM; Elson P; Tyler A; Beatty K; Bokar J; Ivy P; Chen HX; Dowlati A; Dreicer R
    J Clin Oncol; 2010 Jun; 28(17):e284-5; author reply e286-7. PubMed ID: 20439632
    [No Abstract]   [Full Text] [Related]  

  • 4. Tolerability of first-line therapy for metastatic renal cell carcinoma.
    Porta C; Szczylik C
    Cancer Treat Rev; 2009 May; 35(3):297-307. PubMed ID: 19249157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab, sunitinib: osteonecrosis of the jaw.
    Prescrire Int; 2011 Jun; 20(117):155. PubMed ID: 21682016
    [No Abstract]   [Full Text] [Related]  

  • 6. Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.
    Snider KL; Maitland ML
    Target Oncol; 2009 Apr; 4(2):67-76. PubMed ID: 19373440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular toxicity of new agents.
    Maitland ML
    Clin Adv Hematol Oncol; 2008 Sep; 6(9):657-9. PubMed ID: 18827788
    [No Abstract]   [Full Text] [Related]  

  • 8. New study sheds light on angiogenesis inhibitors.
    McBride D
    ONS Connect; 2009 Jun; 24(6):21. PubMed ID: 19552190
    [No Abstract]   [Full Text] [Related]  

  • 9. A phase I study of sunitinib plus bevacizumab in advanced solid tumors.
    Rini BI; Garcia JA; Cooney MM; Elson P; Tyler A; Beatty K; Bokar J; Mekhail T; Bukowski RM; Budd GT; Triozzi P; Borden E; Ivy P; Chen HX; Dolwati A; Dreicer R
    Clin Cancer Res; 2009 Oct; 15(19):6277-83. PubMed ID: 19773375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.
    Mickisch G; Gore M; Escudier B; Procopio G; Walzer S; Nuijten M
    Br J Cancer; 2010 Jan; 102(1):80-6. PubMed ID: 19920817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care.
    Bose D; Meric-Bernstam F; Hofstetter W; Reardon DA; Flaherty KT; Ellis LM
    Lancet Oncol; 2010 Apr; 11(4):373-82. PubMed ID: 20171141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
    Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
    J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Adverse effects of new oncologic therapies].
    Weisshaupt Ch; Budak K; Pestalozzi B
    Praxis (Bern 1994); 2011 Jul; 100(15):885-91; quiz 890. PubMed ID: 21792802
    [No Abstract]   [Full Text] [Related]  

  • 14. Bevacizumab in breast cancer: the best is yet to come?
    Puhalla S; Brufsky A
    Oncology (Williston Park); 2009 Apr; 23(4):332, 335. PubMed ID: 19476262
    [No Abstract]   [Full Text] [Related]  

  • 15. [ASCO 2008. Bevacizumab in advanced renal carcinoma].
    Mansueto G; Longo F
    Tumori; 2008; 94(5):15-23. PubMed ID: 19112964
    [No Abstract]   [Full Text] [Related]  

  • 16. SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer.
    Mayer EL; Dhakil S; Patel T; Sundaram S; Fabian C; Kozloff M; Qamar R; Volterra F; Parmar H; Samant M; Burstein HJ
    Ann Oncol; 2010 Dec; 21(12):2370-2376. PubMed ID: 20497961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.
    Feldman DR; Baum MS; Ginsberg MS; Hassoun H; Flombaum CD; Velasco S; Fischer P; Ronnen E; Ishill N; Patil S; Motzer RJ
    J Clin Oncol; 2009 Mar; 27(9):1432-9. PubMed ID: 19224847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies.
    Girardi F; Franceschi E; Brandes AA
    Oncologist; 2010; 15(7):683-94. PubMed ID: 20547589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
    Miller K; Bergmann L; Albers P; Gschwend J; Jäger E; Keilholz U
    Aktuelle Urol; 2010 May; 41(3):193-6. PubMed ID: 20486036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing outcomes with bevacizumab by better targeting patients and tumors.
    DeMichele A; Fox KR
    Oncology (Williston Park); 2009 Apr; 23(4):339-40. PubMed ID: 19476263
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.